Becaplermin

Becaplermin (brand name Regranex) is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers.[1] It is also known as "platelet-derived growth factor BB".[1]

Becaplermin
Clinical data
Trade namesRegranex
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa699049
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		Topical
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
     NY (what is this?)  (verify)

    Medical uses

    The drug is used for the treatment of diabetic foot ulcers.[2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[4]

    The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator.[1] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [5]

    Contraindications

    Becaplermin must not be used at the site of a skin cancer.[6]

    Adverse effects

    The most common side effects in clinical studies were erythematous rashes.[6]

    A boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[7] Regranex should be used with caution in patients with known malignancy.[1]

    See also

    References
    1. "REGRANEX Gel Highlights of Prescribing Information" (PDF). Smith & Nephew, Inc. Archived from the original (PDF) on 26 August 2016.
    2. Nagai MK, Embil JM (February 2002). "Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers". Expert Opinion on Biological Therapy. 2 (2): 211–8. doi:10.1517/14712598.2.2.211. PMID 11849120.
    3. Wieman TJ, Smiell JM, Su Y (May 1998). "Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study". Diabetes Care. 21 (5): 822–7. doi:10.2337/diacare.21.5.822. PMID 9589248.
    4. Persson U, Willis M, Odegaard K, Apelqvist J (2000). "The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data". Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research. 3 Suppl 1: 39–46. doi:10.1046/j.1524-4733.2000.36027.x. PMID 16464208.
    5. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
    6. FDA Professional Drug Information for Regranex.
    7. Waknine Y (9 June 2008). "Diabetic Ulcer Gel Gets Black Box Warning". Medscape.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.